H

    Health In Tech, Inc. Class A Common Stock (HIT)

    Official site

    TECHNOLOGY • SOFTWARE - APPLICATION • NASDAQ

    $0.96
    -0.02 (-2.04%)

    Market Cap: $64.22M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(4/6)
    Avg Surprise
    -13.89%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.03
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.01+62.0%
    60d ago$-0.01+62.0%
    30d ago$-0.01+62.0%
    7d ago$-0.04-14.3%
    Current$-0.04
    Revenue Consensus
    $10M
    Range$8M - $11M
    3 analysts
    Dec 31, 2026
    EPS Consensus$-0.03
    Range$-0.04 - $-0.02
    2 analysts
    Revenue Consensus
    $16M
    Range$12M - $20M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.04---
    Jun 26
    		$-0.04$-0.03-33.33%Miss-500.0%
    Mar 26
    		$-0.03$-0.02-50.00%Miss-400.0%
    Dec 25
    		$-0.01$-0.01+0.00%Beat+0.0%
    Sep 25
    		$0.01$0.01+0.00%Beat-
    Jun 25
    		$0.01$0.01+0.00%Beat-
    Mar 25
    		$0.01$0.01+0.00%Beat-
    Dec 24
    		$-0.01N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-13.71EV/EBITDA291.33x
    Price/FCF-7.89xFCF Yield-12.67%
    Profitability
    Profit Margin-12.00%Operating Margin-42.70%
    ROE-21.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage2.55x
    Current Ratio2.18xQuick Ratio2.18x
    Trading Statistics
    BetaN/AAvg Volume73.56K
    52-Week High$4.0252-Week Low$0.85

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.00
    SMA 20$1.04
    SMA 50$1.05
    SMA 200$1.29
    EMA 10$1.00
    EMA 20$1.02
    EMA 50$1.06
    EMA 200$1.46

    MACD

    Line: -0.03Signal: -0.02Hist: -0.01

    ADX

    ADX: 12.5+DI: 12.5-DI: 16.8

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down92.0
    PSAR$1.02

    Bollinger Bands

    Upper Band$1.16
    Lower Band$0.92
    %B Position2313%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    38.1

    Momentum Oscillators

    Stoch %K14.3
    Stoch %D21.2
    Williams %R-97.1
    ROC (10d)-5.0%
    Momentum-0.05
    CCI (20d)-90.6
    MFI (14d)51.3

    Volatility Measures

    ATR (14d)$0.06(6.4%)
    StdDev (20d)0.06
    Hist Vol43.3%(High)

    Volume Flow

    VWAP$0.97
    OBV3.7M
    AD Line-48.1M
    CMF (20d)0.166

    Volume Metrics

    Avg Vol (20d)74.7K
    Vol Ratio0.6x
    VWMA (20d)$1.03

    Pivot Points

    R3$1.06
    R2$1.04
    R1$1.01
    Pivot Point$0.99
    S1$0.96
    S2$0.94
    S3$0.91

    Advanced Oscillators

    TSI-14.68
    Ultimate Osc50.5
    KST-69.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.06M$8.77M$7.51M$8.49M$9.31M$8.01M$4.90M$4.46M$5.00M$5.12M$5.22M$5.24M
    Cost of Revenue$4.13M$4.26M$3.38M$3.35M$3.00M$2.66M$1.11M$979,628$974,727$989,911$951,967$855,234
    Gross Profit$3.92M$4.51M$4.13M$5.14M$6.31M$5.36M$3.80M$3.48M$4.03M$4.14M$4.26M$4.38M
    Operating Expenses$7.36M$6.67M$4.30M$4.65M$5.58M$4.87M$4.11M$3.04M$3.49M$3.80M$2.81M$3.87M
    R&D$875,811$920,395$213,113$235,819$582,609$537,721$633,653$718,424$701,626$760,196$673,444$501,121
    SG&A$4.27M$3.46M$3.18M$3.45M$3.78M$3.25M$2.85M$1.81M$1.82M$2.00M$1.26M$2.40M
    Operating Income$-3,438,301$-2,158,155$-170,813$493,523$725,070$480,658$-316,336$438,882$534,936$332,422$1.46M$518,141
    Interest Income$69,568$67,471$104,659$111,699$108,198$85,366$28,774$38,460$31,339$24,312$26,132$14,479
    Interest Expense$0$0$272,928$0$0$0$0$165,000$165,000$165,000$1,104$0
    Income Before Tax$-3,321,074$-2,068,350$-443,741$600,222$833,268$684,423$-110,748$406,739$401,275$191,734$1.48M$532,620
    Income Tax Expense$-809,888$-480,069$-141,184$148,046$202,637$185,831$33,404$30,653$63,268$91,198$478,113$130,225
    Net Income$-2,511,186$-1,588,281$-302,557$452,176$630,631$498,592$-144,152$376,086$338,007$100,536$1.00M$402,395
    EBITDA$-3,070,322$-1,732,354$-137,770$706,504$861,053$735,040$-3,539$833,863$834,723$632,209$1.61M$657,341
    EBIT$-3,390,642$-2,135,821$-548,400$488,523$725,070$599,057$-139,522$533,279$534,936$332,422$1.48M$532,620
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HIT

    News

    Maxim Group Sticks to Their Buy Rating for Health In Tech, Inc. Class A (HIT)

    Maxim Group analyst Allen Klee reiterated a Buy rating for Health In Tech, Inc. Class A (HIT) with a price target of $3.00. This recommendation comes despite Klee's average return of -14.8% and a 29.66% success rate in the Technology sector. Health In Tech recently reported a quarterly revenue of $8.77 million and a GAAP net loss of $1.59 million for the quarter ending March 31.

    The Globe and Mail•8/16/26•
    Bullish

    Craig-Hallum Reaffirms Their Buy Rating on Health In Tech, Inc. Class A (HIT)

    Craig-Hallum analyst George Sutton reiterated a Buy rating on Health In Tech, Inc. Class A (HIT) with a price target of $4.00. Sutton, a 5-star analyst, covers the Technology sector. Health In Tech, Inc. Class A has a Moderate Buy consensus with a target price of $3.50, and recently reported quarterly revenue of $8.06 million and a GAAP net loss of $2.51 million.

    The Globe and Mail•8/16/26•
    Bullish

    Health In Tech, Inc. Class A Common Stock (NASDAQ: HIT) Share Price, HIT Stock News, HIT Share Price & Updates

    This page provides an overview of Health In Tech, Inc. Class A Common Stock (NASDAQ: HIT), including its current stock price, recent performance, and fundamental data. The article displays a real-time stock quote, daily and 52-week ranges, and key financial metrics like market cap, volume, and P/E ratio. It also offers access to financial statements, peer comparisons, and research reports for HIT.

    kalkine.ca•8/15/26•
    Neutral

    Health In Tech Reaffirms 2026 Outlook Amid Q2 Loss

    Health In Tech, Inc. Class A (HIT) reported a Q2 loss but reaffirmed its full-year 2026 revenue guidance of $45 million to $50 million, supported by increasing distribution partners and pipeline revenue. Despite a shift to net loss and negative Adjusted EBITDA, the company highlighted strategic progress with its Three-Year Rate Stabilization Program and the upcoming launch of the HitRix AI-enabled marketplace. Analysts maintain a "Buy" rating for HIT with a $4.00 price target.

    The Globe and Mail•8/15/26•
    Neutral

    Health In Tech Reports Second Quarter 2026 Financial Results

    Health In Tech (Nasdaq: HIT) announced its unaudited financial results for Q2 and H1 2026, reporting $8.1 million in Q2 revenue and a net loss of $2.5 million. Despite a decline in Q2 revenue compared to the previous year, the company saw a 19.9% year-over-year increase in distribution partners and reaffirmed its full-year 2026 revenue guidance of $45 million to $50 million. The company is also progressing with strategic initiatives, including the "Three-Year Rate Stabilization Program" and the upcoming launch of its "HitRix" AI-enabled marketplace platform in the second half of 2026.

    Sahm•8/13/26•
    Somewhat-Bullish

    Frequently Asked Questions About HIT

    Does HIT pay dividends?
    Health In Tech, Inc. Class A Common Stock (HIT) does not currently pay a regular dividend.
    What is HIT's market cap?
    Health In Tech, Inc. Class A Common Stock (HIT) has a market capitalization of $64.22M with a current stock price of $0.96.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In